Noan (Diazepam)

Diazepam enhances the effect of the neurotransmitter gamma‑aminobutyric acid (GABA) at the GABA‑A receptor. By binding to a specific benzodiazepine site, it increases the frequency of chloride channel opening, leading to neuronal hyperpolarisation and reduced excitability, which produces anxiolytic, sedative, muscle‑relaxant and anticonvulsant actions.

The dose of Noan is individualized by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and concomitant therapies. Healthcare professionals determine the appropriate amount, route (intramuscular or intravenous), and frequency according to clinical guidelines and patient response.

Diazepam is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be used during pregnancy only when the potential benefit justifies the risk. Diazepam passes into breast milk; therefore, breastfeeding mothers should discuss alternatives with their healthcare provider.

To order Noan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Noan (diazepam) has a relatively long half‑life compared with agents such as lorazepam or midazolam, providing prolonged anxiolytic and anticonvulsant coverage. Its rapid onset when given intravenously makes it suitable for emergency seizure control, while its longer duration can be advantageous for sustained sedation but may increase the risk of accumulation in elderly or renally impaired patients.

Noan should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture and extreme temperatures. Do not freeze. Inspect the vial for particulate matter before use and discard any solution that appears discolored or cloudy.

Noan is supplied as a sterile injectable solution for intramuscular or intravenous injection. The vial is reconstituted only if required by the specific formulation, and the dose is drawn into a sterile syringe. Administration should be performed by qualified healthcare personnel following aseptic technique and appropriate dosing guidelines.

Serious risks include respiratory depression, especially when combined with other CNS depressants; profound hypotension; paradoxical reactions such as agitation or aggression; development of physical dependence and withdrawal syndrome after prolonged use; and rare but severe liver injury. Patients should be monitored closely for these events.

Noan is contraindicated in patients with known hypersensitivity to diazepam or any benzodiazepine, those with acute narrow‑angle glaucoma, severe respiratory insufficiency, or severe hepatic impairment. Caution is also advised in individuals with a history of substance use disorder, myasthenia gravis, or severe depression, and it should be avoided in newborns and premature infants.